Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Conditions
Interventions
Baricitinib
Placebo
Locations
93
Czechia
Kozni ambulance Kutna Hora, s.r.o.
Kutná Hora, Central Bohemia, Czechia
Clintrial, s.r.o.
Prague, Hl. M. Praha, Czechia
Fakultni nemocnice Kralovske Vinohrady
Prague, Hl. M. Praha, Czechia
Fakultni Nemocnice v Motole
Prague, Hl. M. Praha, Czechia
Nemocnice Na Bulovce
Prague, Hl. M. Praha, Czechia
Nemocnice Novy Jicin a.s.
Nový Jičín, Moravskoslezský kraj, Czechia
Start Date
November 23, 2017
Primary Completion Date
December 6, 2018
Completion Date
August 16, 2019
Last Updated
August 18, 2020
NCT07262983
NCT06389136
NCT06342713
NCT07290803
NCT07223697
NCT07265479
Lead Sponsor
Eli Lilly and Company
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions